Literature DB >> 2499250

Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

J Fung-Tomc1, T J Dougherty, F J DeOrio, V Simich-Jacobson, R E Kessler.   

Abstract

One hundred clinical isolates resistant to ceftazidime and/or cefotaxime were examined for susceptibility to cefepime. The most frequently encountered ceftazidime-cefotaxime-resistant strains belonged to the genera Enterobacter, Pseudomonas, and Citrobacter. Among these strains, 92% were resistant to cefoperazone, 91% were resistant to cefotaxime, 84% were resistant to ceftazidime, and 6% were resistant to cefepime. Of the members of the family Enterobacteriaceae, 57% were resistant to ceftriaxone. The six strains resistant to cefepime were all Pseudomonas aeruginosa and were resistant to both cefotaxime and ceftazidime. Cefepime-resistant P. aeruginosa strains had exceptionally high levels of beta-lactamase activity, higher than the levels found in strains resistant to ceftazidime but susceptible to cefepime. The beta-lactamases from the cefepime-resistant strains were type I (Richmond-Sykes), were constitutively produced, and did not have increased affinity or hydrolytic activity for cefepime. Thus, cefepime was active against most gram-negative bacteria which have developed resistance to the broad-spectrum cephalosporins, and resistance to cefepime in P. aeruginosa appears to be associated with higher beta-lactamase levels than in cefepime-susceptible strains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499250      PMCID: PMC172467          DOI: 10.1128/AAC.33.4.498

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

2.  A spectrophotometric assay of beta-lactamase action on penicillins.

Authors:  S G Waley
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

3.  A direct spectrophotometric assay and determination of Michaelis constants for the beta-lactamase reaction.

Authors:  A Samuni
Journal:  Anal Biochem       Date:  1975-01       Impact factor: 3.365

Review 4.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

5.  Reduced sensitivity to beta-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections.

Authors:  A King; K Shannon; S Eykyn; I Phillips
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

6.  Effect of antibiotic use on the incidence of cephalosporin resistance in two Australian hospitals.

Authors:  R A Benn; R J Kemp
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

7.  Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams.

Authors:  H Vu; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

Authors:  J Fung-Tomc; E Huczko; M Pearce; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

9.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

10.  Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism.

Authors:  R L Then; P Angehrn
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

View more
  21 in total

1.  Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.

Authors:  J Martínez-Beltrán; R Cantón; J Liñares; J García de Lomas; C Gimeno; F Tubau; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

4.  Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 6.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.

Authors:  J A Washington; R N Jones; E H Gerlach; P R Murray; S D Allen; C C Knapp
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

8.  Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

Authors:  J Hübner; D Hartung; A Kropec; F D Daschner
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

9.  Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.

Authors:  L O Gentry; G Rodriguez-Gomez
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Differential effects of bismuth and salicylate salts on the antibiotic susceptibility of Pseudomonas aeruginosa.

Authors:  P Domenico; R O'Leary; B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.